ArticleBMC infectious diseases2026
Serotype and antimicrobial susceptibility patterns of Vibrio cholerae in cholera outbreak areas of East and Central Oromia Region, Ethiopia, 2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCholera is an acute diarrheal infection caused by the consumption of food or water contaminated with Vibrio cholerae serotypes Ogawa and Inaba. Historically, Vibrio cholerae has remained susceptible to several key antibiotics. However, resistance to older antibiotics has been increasingly reported worldwide. The objective of this study was to assess the distribution of Vibrio cholerae serotypes and their susceptibility patterns in the cholera outbreak areas of the East and central Oromia region, Ethiopia, 2024.
methodThe study was conducted on isolates recovered from stool specimens collected from Cholera Outbreak areas of East and Central Oromia Region in 2024. The study design used was a laboratory-based retrospective cross-sectional study. Serotyping and antimicrobial susceptibility testing were performed on isolates identified after enrichment in alkaline peptone water, (BIOMARK Laboratories, India). Presumptive screening of the isolates was performed using the Oxidase test (HiMedia, India), string test (Liofilchem, Italy), and other standard biochemical tests. Presumptive identification with O1 and O139 antisera (Hardy Diagnostics, USA) was carried out using the slide agglutination method with polyvalent O1 or O139 antisera. Antimicrobial susceptibility patterns were assessed using the disk diffusion method.
resultsAll isolates tested for identification of Vibrio cholerae suspects were found to be serogroup O1. Of these Ogawa accounts for 62% and Inaba for 38%. Complete (100%) resistance was observed for cefepime, ceftazidime, piperacillin, and trimethoprim-sulfamethoxazole. Additionally, very high resistance rates were found for cefuroxime sodium (93.0%) and ampicillin-sulbactam (93%). Tetracycline also exhibited significant resistance at 76.2%, while cefoxitin and ampicillin showed substantial resistance at 56.1% and 40.5%, respectively. Ciprofloxacin (69.0%) and levofloxacin were moderately effective, but also displayed notable resistance rates 31.0% and 26.2%, respectively. CONCLUSION AND
interpretationAll Vibrio cholerae isolates identified in this study belong to serogroup O1, with the Ogawa serotype being more prevalent than Inaba. The isolates demonstrated extensive resistance to multiple commonly used antibiotics, including a complete resistance to several cephalosporins, piperacillin and trimethoprim-sulfamethoxazole, alongside high resistance to tetracycline and other agents. Although ciprofloxacin and levofloxacin showed comparatively better activity, the presence of considerable resistance highlights a narrowing range of effective treatment options and underscores the need for ongoing antimicrobial resistance monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.